Mandate

Vinge has advised Ambea on a rights issue

Vinge has advised Ambea AB (publ) on a fully subscribed rights issue, which will provide Ambea with issue proceeds amounting to approximately SEK 1,215 million before costs.

The new shares are expected to be admitted to trading on Nasdaq Stockholm on 25 June 2019.

Ambea is the market leading private care provider in Sweden, Norway and Denmark respectively, with about 900 units and around 26,000 employees. Through the brands Nytida, Vardaga, Lära, Klara, Stendi and Altiden, Ambea provides housing, support, education and personnel for health and social care.

Ambea is listed on Nasdaq Stockholm, Mid cap.

Vinge’s team consisted primarily of Charlotte Levin, Nils Fredrik Dehlin, Annika Nyberg Ekenberg and Marcus Gustavsson.
 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025